Abbott To Pay $1.6B To Settle Depakote Allegations
Abbott Laboratories Inc. pled guilty to drug misbranding and agreed to pay $1.6 billion on Monday to resolve state and federal investigations into its off-label marketing of the anti-seizure drug Depakote...To view the full article, register now.
Already a subscriber? Click here to view full article